Education
About Us
Working with TipRanks
Follow Us
Opko Health Inc (OPK)
NASDAQ:OPK
Earnings Data
Report Date
May 12, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call communicated substantial strategic and operational progress — meaningful ModeX pipeline advancement, high-value partnerships (Regeneron, Merck), nondilutive government funding (BARDA), a stronger cash position, and active share repurchases. Offsetting these positives are near-term financial pressures: YoY revenue decline driven by divestitures and milestone timing, Q4 net loss vs prior-year income, higher R&D spend and anticipated elevated costs in 2026, plus seasonal/weather impacts on Q1 volumes. Overall, the company is positioned for longer-term value creation but faces short-term headwinds as it invests through a transition year.Company Guidance
Strong liquidity and active capital return
Ended Q4 2025 with $369 million in cash and cash equivalents; deployed >$109 million in convertible note and common stock repurchases during 2025 and almost $230 million since 2024; repurchased 9.8 million shares in Q4 and 34.6 million shares for ~ $47 million in 2025; ~$113 million remaining under buyback authorization.
ModeX pipeline acceleration and high-value partnerships
ModeX now has multiple clinical-stage programs (3 in clinic, 2 entering soon). Key assets: MDX2001 (tetraspecific) dosed >25 patients and reached ~10x starting dose with acceptable safety; MDX2004 (trispecific immune rejuvenator) entered Phase I in Australia and Israel; MDX2003 received IND approval in Australia with first-in-human trials imminent; EBV vaccine partnered with Merck (Phase I >200 subjects). Entered collaboration with Regeneron with potential milestone payments >$1 billion and full funding/reimbursement for selected programs.
Meaningful nondilutive funding and government support
Received $28.5 million in BARDA funding in 2025 (total $54 million since inception); FDA cleared IND for MDX2301 (COVID multispecific antibody) to enter clinic H1 2026; BARDA will assume clinical trial costs for supported programs.
Diagnostics transformation and 4Kscore momentum
Completed sale of BioReference oncology assets (transformed BioReference into a regionally focused clinical lab with national 4Kscore franchise). Remaining BioReference operations generated ~ $300 million in 2025 revenue. Workforce reduced ~29% to ~1,400 FTEs to streamline cost base. 4Kscore: Q4 revenue $7 million (more than +16% YoY vs $6M in 2024) and test volume +6% YoY; new label (no DRE required) should support primary care adoption and margin expansion.
Pharmaceutical commercial positives
Pharmaceutical product sales increased to $43.7 million from $37.4 million in Q4 2024 (+~17%), driven by foreign exchange tailwinds and higher international volumes. Pfizer gross profit share was $12.5 million in Q4 (+30% YoY), the highest recorded to date. First royalty payment from mazdutide (Lilly/Innovent in China) contributed $4.3 million in Q4.
Clear 2026 financial & operational roadmap
Management provided FY2026 guidance: revenue $530–$560 million (services $300–$312M; product $160–$170M; partnerships $70–$80M), R&D investment $125–$135 million offset by $22–$26M in BARDA/Regeneron reimbursements, and plan to continue accelerating share repurchases.
OPK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
OPK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 26, 2026 | $1.20 | $1.20 | 0.00% |
Oct 29, 2025 | $1.43 | $1.46 | +2.10% |
Jul 31, 2025 | $1.28 | $1.19 | -7.03% |
Apr 30, 2025 | $1.38 | $1.35 | -2.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Opko Health Inc (OPK) report earnings?
Opko Health Inc (OPK) is schdueled to report earning on May 12, 2026, After Close (Confirmed).
What is Opko Health Inc (OPK) earnings time?
Opko Health Inc (OPK) earnings time is at May 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is OPK EPS forecast?
OPK EPS forecast for the fiscal quarter 2026 (Q1) is -0.08.